Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers

Video

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

At the 2022 International Gastric Cancer Conference, Sam Klempner, MD, of Massachusetts General Hospital, spoke to CancerNetwork® about minimal residual disease (MRD) and how it’s used to inform the decision-making process when determining treatment for patients with gastrointestinal cancer.

Transcript:

The platforms to study minimal residual disease are continuing to evolve. I don’t think either of these may be the ultimate final say, but currently there are 2 broad categories. [With a tumor-informed approach], a patient’s tissue sample is subjected to broad sequencing often using whole-exome sequencing and then matched to a normal sample to filter out somatic mutations that are not from tumor cells and you use that sequencing data to predict clonal mutations. These are things that are going to be present in all of the tumor cells, and then you select variants and probe the blood for those variants. If you find them, you would call the assay positive and the person would be [considered to have positive] MRD. If you don’t, the test would be negative.

The other alternative is tumor uninformed or a tumor-naive approach. Ultimately the goal is the same, except you’re not using a tissue benchmark. In this case, you have a predetermined panel of genes and you probe the plasma, the cell-free DNA, for these genes along with a normal match to again filter out somatic alterations [that are] not from tumor cells. Then you come up with a list of potentially tumor-specific alterations and you probe the blood. Tumor-naive approaches often incorporate additional parameters such as methylated DNA detection to improve the sensitivity. Additional parameters are being explored and I suspect that both technologies will continue to improve in sensitivity and specificity over the coming months to years.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content